CN107927793A - 预防或减轻人体便秘的合生元制剂及其制备方法 - Google Patents
预防或减轻人体便秘的合生元制剂及其制备方法 Download PDFInfo
- Publication number
- CN107927793A CN107927793A CN201711216931.5A CN201711216931A CN107927793A CN 107927793 A CN107927793 A CN 107927793A CN 201711216931 A CN201711216931 A CN 201711216931A CN 107927793 A CN107927793 A CN 107927793A
- Authority
- CN
- China
- Prior art keywords
- parts
- human body
- preparation
- symphysis unit
- unit preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 56
- 206010010774 Constipation Diseases 0.000 title claims abstract description 38
- 230000002265 prevention Effects 0.000 title claims abstract description 28
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims abstract description 28
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 25
- 230000000116 mitigating effect Effects 0.000 claims abstract description 23
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 18
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 18
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 18
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 17
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 17
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 17
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 17
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 17
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 16
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 16
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 16
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 11
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 11
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 6
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 208000024891 symptom Diseases 0.000 abstract description 5
- 239000006041 probiotic Substances 0.000 description 20
- 235000018291 probiotics Nutrition 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 241000186000 Bifidobacterium Species 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 235000013406 prebiotics Nutrition 0.000 description 8
- 230000013872 defecation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229960003487 xylose Drugs 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 244000298715 Actinidia chinensis Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241001495180 Arthrospira Species 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000191998 Pediococcus acidilactici Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000003677 abuse test Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种预防或减轻人体便秘的合生元制剂,包括以下重量份数的组分:嗜酸乳杆菌10‑100份、干酪乳酸杆菌10‑100份、植物乳杆菌10‑100份、乳双歧杆菌10‑100份、长双歧杆菌10‑100份、低聚木糖50‑700份和棉子糖50‑700份。本发明还涉及一种预防或减轻人体便秘的合生元制剂的制备方法。本发明的预防或减轻人体便秘的合生元制剂具有可以明显预防或减轻人体便秘的症状的功效。
Description
技术领域
本发明涉及保健食品技术领域,特别涉及一种预防或减轻人体便秘的合生元制剂及其制备方法。
背景技术
合生元又称合生素或共生元,由GIBAON(1995)首先提出,是益生菌与益生元的复合制品,其特点是同时发挥益生菌和益生元的作用。现已广泛地用于人类和动物保健与疾病预防治疗过程中,它有使用高效且无残留等众多优点,今后有成为抗生素预防治疗疾病替代品的趋势。合生元是“益生菌和益生元的混合制剂”。
益生菌(Probiotic)又称为益生素,是一类能产生确切健康功效从而改善宿主微生态平衡、发挥有益作用的活性有益微生物的总称。作为一种新型的“保健医生”,益生菌在防治消化道疾病、帮助消化吸收和刺激免疫系统等方面疗效显著,在食品、畜牧、医药等领域都被大量应用。通过口服或其他方式投入,益生菌可在黏膜表面处改善微生物区系的屏障功能或刺激特异性与非特异性免疫生成一种活的微生物制剂,同时还可以改善宿主肠道微生态平衡和增强健康。益生菌常见的有嗜酸乳杆菌、干酪乳杆菌、植物乳杆菌、双歧杆菌、短乳杆菌、保加利亚乳杆菌、乳酸片球菌、粪链球菌、嗜热链球菌、纳豆芽胞杆菌、枯草芽胞杆菌、酿酒酵母等。
益生元也叫“化学益生素”,是一种不易被机体消化但可选择性刺激肠道内有益菌(双歧杆菌、乳酸菌等)的生长或增强有益菌的活性,且不被有害菌群利用,从而促进机体健康的益菌制品。益生元作为益生菌刺激物,具有促进益生菌增殖、改善肠道菌群、保健等功能,因此也被称为是一种功能性食品。主要包括低聚糖(低聚果糖、低聚木糖、低聚半乳糖、低聚异麦芽糖等)及现阶段所发现的微藻(螺旋藻、节旋藻等)和天然植物(蔬菜、中草药、野生植物等)等。
嗜酸乳杆菌属于乳杆菌属,革兰氏阳性杆菌,形态呈细长杆状,最适生长温度为35~38℃,20℃以下不生长,耐热性差。最适pH为5.5~6.0,耐酸性强,能在其它乳酸菌不能生长的环境中生长繁殖。嗜酸乳杆菌是人体肠道重要的益生菌,嗜酸乳杆菌在肠道内的数目是评价机体健康程度的重要指标,因为其良好的保健功能,如具备酸和胆汁盐耐受性,粘附人体上皮细胞,定植肠道产生细菌素,促进乳糖耐受性以及消化,降低肠道pH,改善胃肠道功能,降低胆固醇,降低氨和其他毒性物质,产生B族维生素,使遭受抗生素破坏的紊乱肠道菌群恢复正常,治疗和抑制轮状病毒引起的严重腹泻,刺激免疫反应等。
干酪乳杆菌属于乳杆菌属,革兰氏阳性菌,其菌体长短不一,两端呈方形,常成链;菌落粗糙,灰白色,有时呈微黄色,能发酵多种糖,最适生长温度为37℃。作为益生菌的一种,干酪乳杆菌能够耐受有机体的防御机制,其中包括口腔中的酶、胃液中低pH值和小肠的胆汁酸等。所以干酪乳杆菌进入人体后可以在肠道内大量存活,能起到调节肠内菌群平衡、促进人体消化吸收,抗肿瘤,降血压等作用,同时,干酪乳杆菌具有高效降血压降胆固醇,并且能够诱导产生抗菌素,促进细胞分裂,产生抗体免疫,增强人体免疫及预防癌症和抑制肿瘤生长等作用。干酪乳杆菌还具有缓解乳糖不耐症,缓解过敏等益生保健作用。
植物乳杆菌属于乳杆菌属,革兰氏阳性、兼性厌氧菌,菌体直或弯的杆状,单个、有时成对或成链状,最适生长温度为30~35℃,作为益生菌具有一定的免疫调节作用;对致病菌有抑制作用;降低血清胆固醇含量和预防心血管疾病;维持肠道内菌群平衡;促进营养物质吸收;缓解乳糖不耐症;抑制肿瘤细胞的形成等。
乳双歧杆菌属于双歧杆菌属,革兰氏阳性、厌氧菌,菌体形态呈短杆状,单个、成对或成簇分布,两端呈楠球形,顶端有分叉。与其他的双歧杆菌属的菌种一样具有调节肠道菌群和增强免疫力的功能。乳双歧杆菌主要特征为产甲酸盐以及可以在牛奶中生长。对于习惯引用牛奶的人群来说,含乳双歧杆菌的双歧杆菌菌群往往是其体内的益生菌优势菌群。
长双歧杆菌属于双歧杆菌属,是人体肠道中常见的双歧杆菌,能够抑制一些维生素分解酶的活性,使机体内的维生素免遭破坏;自身还能合成人体所需多种蛋白质和各类氨基酸及维生素,从而为机体提供直接的营养成分;长双歧杆菌能够增强机体免疫功能以及能够改善人体脂质的代谢素乱,降低血清中的三酰甘油和胆固醇的含量,食用长双歧杆菌能够降低血压、血脂并有效预防也、脑血管等疾病的发生。此外,长双歧杆菌取自健康人体肠道,筛选出完全适合人体之菌株,符合美国食品即药物检验局(FDA)核准可使用于一般食品类的双歧杆菌。
低聚木糖又称木寡糖,是由2-7个木糖分子以β-1,4糖苷键结合而成的功能性聚合糖,低聚木糖有相当于蔗糖40%的甜度,且甜味纯正,在本方中还是良好的甜味剂,此外低聚木糖还有很强的增殖肠道益生菌的功能,可以选择性地促进肠道双歧杆菌的增殖活性。低聚木糖对双歧杆菌、乳酸菌等益生菌有高选择性增殖效果,但对大肠杆菌、肠球菌、梭状芽孢杆菌等病原菌则有明显的抑制作用。因此作为一种附加值高、市场前景看好的功能性食品添加剂,是目前国内外竞相研究开发的功能性低聚糖之一。为使配方中的益生菌增值,我们在配方中添加了益生元。低聚木糖与其他低聚糖相比,用量低,但效果更明显。低聚木糖在较低剂量下即可使乳双歧杆菌成倍增加,且低聚木糖水分活度较其他益生元更低,能更好地与益生菌复配,保障益生菌在较长保质期内保持活性。为了使本品功效更显著,我们添加了低聚木糖,使产品成为合生元制剂。
棉子糖(Raffinose)又称蜜三糖,其组成是α-D-吡喃半乳糖(1→6)α-D-吡喃葡萄糖(1→2)β-D-呋喃果糖,分子式为C18H32O16。纯净的棉子糖为长针状白色或淡黄色结晶体。它易溶于水,微溶于乙醇等极性溶剂,不溶于石油醚等非极性溶剂。棉子糖在自然界植物中广泛存在,人们熟知的功能性低聚糖--大豆低聚糖中的主要功效成分之一就是棉子糖,同时,在很多蔬菜(卷心菜、花椰菜、马铃薯、甜菜、洋葱等)、水果(葡萄、香蕉、猕猴桃等)、稻谷(小麦、水稻、燕麦等)一些油料作物的籽仁中(大豆、葵花籽、棉籽、花生等)。由于棉子糖不能被胃和小肠消化吸收,它对人体有益的生理功能是通过增殖肠道内的有益菌群乳酸杆菌、双歧杆菌等来体现的。消化道内的有益菌群可以选择性的对棉子糖进行发酵利用,使自身生长速度加快,数量增加;而有害菌群难以利用棉子糖,数量减少,形成此消彼长的健康肠道菌群环境。因此为了使配方功效更显著,我们添加了棉子糖。
现在市场上所售合生元产品存在结构简单、功能单一和效果不明显的不足。
发明内容
本发明所要解决的技术问题是:提供一种功效明显的预防或减轻人体便秘的合生元制剂及其制备方法。
为了解决上述技术问题,本发明采用的技术方案为:
一种预防或减轻人体便秘的合生元制剂,包括以下重量份数的组分:嗜酸乳杆菌10-100份、干酪乳酸杆菌10-100份、植物乳杆菌10-100份、乳双歧杆菌10-100份、长双歧杆菌10-100份、低聚木糖50-700份和棉子糖50-700份。
本发明还提供一种上述的预防或减轻人体便秘的合生元制剂的制备方法,按照上述的预防或减轻人体便秘的合生元制剂的组分,将低聚木糖和棉子糖于60-65℃条件下进行干燥,干燥时间约为2h,使水分含量控制在<3%;称取各组分在室温条件下用多向运动型混合机混合约30min,使混合均匀,得到总物料;过100目筛;用自动灌装机分装成800袋,操作间温度18-26℃,相对湿度<30℃以下。
本发明的有益效果在于:
本发明采用上述组分设计,一则配方操作简单,二则获得的合生元制剂能够有效预防或减轻人体便秘的症状,并且具有安全有效、受众广泛以及易于推广应用的优点。
具体实施方式
为详细说明本发明的技术内容、所实现目的及效果,以下结合实施方式予以说明。
本发明最关键的构思在于:采用上述组分设计,以有效预防或减轻人体便秘的症状。
本发明提供一种预防或减轻人体便秘的合生元制剂,包括以下重量份数的组分:嗜酸乳杆菌10-100份、干酪乳酸杆菌10-100份、植物乳杆菌10-100份、乳双歧杆菌10-100份、长双歧杆菌10-100份、低聚木糖50-700份和棉子糖50-700份。
本发明还提供一种上述的预防或减轻人体便秘的合生元制剂的制备方法,按照上述的预防或减轻人体便秘的合生元制剂的组分,将低聚木糖和棉子糖于60-65℃条件下进行干燥,干燥时间约为2h,使水分含量控制在<3%;称取各组分在室温条件下用多向运动型混合机混合约30min,使混合均匀,得到总物料;过100目筛;用自动灌装机分装成800袋,操作间温度18-26℃,相对湿度<30℃以下。
从上述描述可知,本发明的有益效果在于:
本发明采用上述组分设计,一则配方操作简单,二者,获得的合生元制剂能够有效预防或减轻人体便秘的症状,并且具有安全有效、受众广泛以及易于推广应用的优点。
本发明的预防或减轻人体便秘的合生元制剂中:
进一步的,合生元制剂包括以下重量份数的组分:嗜酸乳杆菌10-80份、干酪乳酸杆菌15-95份、植物乳杆菌20-100份、乳双歧杆菌10-90份、长双歧杆菌25-70份、低聚木糖50-650份和棉子糖50-630份。
更进一步的,合生元制剂包括以下重量份数的组分:嗜酸乳杆菌30份、干酪乳酸杆菌90份、植物乳杆菌100份、乳双歧杆菌80份、长双歧杆菌50份、低聚木糖300份和棉子糖150份。
由上述描述可知,上述组分设计为合生元制剂的优选的组分设计,具有配方操作简单,且预防或减轻人体便秘的症状的功效更加明显的技术效果。
本发明的实施例一为:
本实施例的预防或减轻人体便秘的合生元制剂,采用下述方法准备获得:
将低聚木糖和棉子糖于60-65℃条件下干燥约2h,使水分含量控制在<3%;称取嗜酸乳杆菌30份、干酪乳酸杆菌90份、植物乳杆菌100份、乳双歧杆菌80份、长双歧杆菌50份、低聚木糖300份和棉子糖150份,在室温条件下用多向运动型混合机混合约30min,使混合均匀,得到总物料;过100目筛;用自动灌装机分装成800袋,操作间温度18-26℃,相对湿度<30℃以下。
本发明的实施例二为:
本实施例的预防或减轻人体便秘的合生元制剂,其制备方法与实施例一基本相同,区别仅在于各组分的具体重量份数为:
嗜酸乳杆菌10份、干酪乳酸杆菌10份、植物乳杆菌10份、乳双歧杆菌10份、长双歧杆菌10份、低聚木糖50份和棉子糖50份。
本发明的实施例三为:
本实施例的预防或减轻人体便秘的合生元制剂,其制备方法与实施例一基本相同,区别仅在于各组分的具体重量份数为:
嗜酸乳杆菌100份、干酪乳酸杆菌100份、植物乳杆菌100份、乳双歧杆菌100份、长双歧杆菌100份、低聚木糖700份和棉子糖700份。
本发明的实施例四为:
本实施例的预防或减轻人体便秘的合生元制剂,其制备方法与实施例一基本相同,区别仅在于各组分的具体重量份数为:
嗜酸乳杆菌50份、干酪乳酸杆菌50份、植物乳杆菌50份、乳双歧杆菌50份、长双歧杆菌50份、低聚木糖450份和棉子糖450份。
本发明的实施例五为:
本实施例的预防或减轻人体便秘的合生元制剂,其制备方法与实施例一基本相同,区别仅在于各组分的具体重量份数为:
嗜酸乳杆菌10份、干酪乳酸杆菌15份、植物乳杆菌20份、乳双歧杆菌10份、长双歧杆菌25份、低聚木糖50份和棉子糖50份。
本发明的实施例六为:
本实施例的预防或减轻人体便秘的合生元制剂,其制备方法与实施例一基本相同,区别仅在于各组分的具体重量份数为:
嗜酸乳杆菌80份、干酪乳酸杆菌95份、植物乳杆菌100份、乳双歧杆菌90份、长双歧杆菌70份、低聚木糖650份和棉子糖630份。
人体试食实验
病例资料:临床应用600例,女性300例,年龄20-85岁,男性300例,龄20-85岁,平均年龄50岁。临床表现为排便困难、费力,大便干结,部分像羊粪状。如厕次数少,频率低,轻者2-4天一次,重者7-10天一次。患者治疗前均停用抗生素药物及各种润通肠道药物。每50例女性和每50例男性作为一组试验例(即一组试验例中包括临床应用100例),年依次获得试验例1-6。
治疗方法:试验例1-6的便秘者依次对应口服实施例1-6中的合生元制剂,早中晚各一次,4个星期为一个疗程。
治疗结果评价:
治愈:排便不费力气,10min内排便结束,便软,如同香蕉状。排便频率达到1天1次。
显效:排便轻度费力,耗时不超过15min,至少2天一次。粪便略干,成型。
好转:治疗排便费力、耗时、频次较治疗前有所改善,但达不到显效的标准。。
无效:治疗前后排便无明显变化。
治疗效果:试验例1-6中,每个试验例中的100例便秘者,治愈35例,占比为35%;显效31例,占比为31%;好转16例,占比为16%;无效18例,占比为18%。总有效果占比为82%。
综上所述,本发明提供的预防或减轻人体便秘的合生元制剂具有可以明显预防或减轻人体便秘的症状的功效。
以上所述仅为本发明的实施例,并非因此限制本发明的专利范围,凡是利用本发明说明书内容所作的等同变换,或直接或间接运用在相关的技术领域,均同理包括在本发明的专利保护范围内。
Claims (8)
1.一种预防或减轻人体便秘的合生元制剂,其特征在于,包括以下重量份数的组分:嗜酸乳杆菌10-100份、干酪乳酸杆菌10-100份、植物乳杆菌10-100份、乳双歧杆菌10-100份、长双歧杆菌10-100份、低聚木糖50-700份和棉子糖50-700份。
2.根据权利要求1所述的预防或减轻人体便秘的合生元制剂,其特征在于,包括以下重量份数的组分:嗜酸乳杆菌10-80份、干酪乳酸杆菌15-95份、植物乳杆菌20-100份、乳双歧杆菌10-90份、长双歧杆菌25-70份、低聚木糖50-650份和棉子糖50-630份。
3.根据权利要求2所述的预防或减轻人体便秘的合生元制剂,其特征在于,包括以下重量份数的组分:嗜酸乳杆菌30份、干酪乳酸杆菌90份、植物乳杆菌100份、乳双歧杆菌80份、长双歧杆菌50份、低聚木糖300份和棉子糖150份。
4.一种权利要求1-3任意一项所述的预防或减轻人体便秘的合生元制剂的制备方法,其特征在于,按照权利要求1-3任意一项所述的预防或减轻人体便秘的合生元制剂的组分,分别获取各组分并混合,得到混合物料;然后将混合物料进行分装,即得所述合生元制剂。
5.根据权利要求4所述的预防或减轻人体便秘的合生元制剂的制备方法,其特征在于,将低聚木糖和棉子糖于60-65℃条件下进行干燥,使水分含量控制在小于3%。
6.根据权利要求4所述的预防或减轻人体便秘的合生元制剂的制备方法,其特征在于,将称取的各组分投入多向运动型混合机中进行混合,混合时间为25-35min。
7.根据权利要求4所述的预防或减轻人体便秘的合生元制剂的制备方法,其特征在于,将各组分的混合物料过100目筛。
8.根据权利要求4所述的预防或减轻人体便秘的合生元制剂的制备方法,其特征在于,采用自动灌装机进行所述分装,自动灌装机中分装操作间的温度为18-26℃,相对湿度为30℃以下。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711216931.5A CN107927793A (zh) | 2017-11-28 | 2017-11-28 | 预防或减轻人体便秘的合生元制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711216931.5A CN107927793A (zh) | 2017-11-28 | 2017-11-28 | 预防或减轻人体便秘的合生元制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107927793A true CN107927793A (zh) | 2018-04-20 |
Family
ID=61949450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711216931.5A Pending CN107927793A (zh) | 2017-11-28 | 2017-11-28 | 预防或减轻人体便秘的合生元制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107927793A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109432136A (zh) * | 2018-10-31 | 2019-03-08 | 张志澎 | 一种益生菌组合制剂及其制备方法和应用 |
CN114651984A (zh) * | 2022-03-30 | 2022-06-24 | 微康益生菌(苏州)股份有限公司 | 干酪乳杆菌lc89及包含其的微生物制剂在制备缓解功能性便秘的产品中的应用 |
CN116286371A (zh) * | 2023-03-07 | 2023-06-23 | 深圳零一生命科技有限责任公司 | 一种提高菌株冻干效果的冻干保护剂配方 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496575A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种含短肽和益生菌的特殊营养食品配方 |
CN106616586A (zh) * | 2016-10-14 | 2017-05-10 | 千亿达(天津)科技有限公司 | 一种肠胃保健益生菌粉 |
CN107048360A (zh) * | 2017-04-11 | 2017-08-18 | 姜红成 | 制备具有调理胃肠道润肠通便功能的植物酵素的发酵组合物及制法 |
-
2017
- 2017-11-28 CN CN201711216931.5A patent/CN107927793A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496575A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种含短肽和益生菌的特殊营养食品配方 |
CN106616586A (zh) * | 2016-10-14 | 2017-05-10 | 千亿达(天津)科技有限公司 | 一种肠胃保健益生菌粉 |
CN107048360A (zh) * | 2017-04-11 | 2017-08-18 | 姜红成 | 制备具有调理胃肠道润肠通便功能的植物酵素的发酵组合物及制法 |
Non-Patent Citations (3)
Title |
---|
胡学智: "益生元的生理功能、制造和应用(二) ", 《江苏调味副食品》 * |
胡学智: "益生菌、益生元和消化酶 ", 《工业微生物》 * |
陈忠秀等: "益生菌的应用现状和发展前景 ", 《中国微生态学杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109432136A (zh) * | 2018-10-31 | 2019-03-08 | 张志澎 | 一种益生菌组合制剂及其制备方法和应用 |
CN114651984A (zh) * | 2022-03-30 | 2022-06-24 | 微康益生菌(苏州)股份有限公司 | 干酪乳杆菌lc89及包含其的微生物制剂在制备缓解功能性便秘的产品中的应用 |
CN116286371A (zh) * | 2023-03-07 | 2023-06-23 | 深圳零一生命科技有限责任公司 | 一种提高菌株冻干效果的冻干保护剂配方 |
CN116286371B (zh) * | 2023-03-07 | 2023-07-18 | 深圳零一生命科技有限责任公司 | 一种提高菌株冻干效果的冻干保护剂配方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106619743A (zh) | 一种具有降血糖作用的益生菌固体饮料及其制备方法 | |
CN105146614B (zh) | 一种功能性钙果酵素、酵素饮料及其生产方法 | |
CN104758318B (zh) | 一种降低断奶仔猪腹泻率的复合制剂及其制备方法 | |
US9101651B2 (en) | Lactobacillus rhamnosus and weight control | |
CN102511720B (zh) | 一种水苏糖婴幼儿营养米粉和其制备方法 | |
CN108991327A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN109123295A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN104642870B (zh) | 一种益生元组合物 | |
CN105995976A (zh) | 一种具有降脂减肥作用的综合酵素粉及其应用 | |
CN109628358A (zh) | 一种复合益生菌及其应用 | |
CN104770816A (zh) | 一种西瓜汁益生菌发酵饮料及其制备方法 | |
CN109666615A (zh) | 一种益生菌组合物及其应用 | |
CN103271274B (zh) | 一种营养保健粥 | |
CN101560523B (zh) | 基于五株益生菌混合发酵培养物的营养组合物 | |
CN108740251A (zh) | 一种改善便秘的益生菌凝胶糖果及其制备方法 | |
CN109846035A (zh) | 一种具有体重控制功效的复合益生菌组合物 | |
CN104489462B (zh) | 一种低聚木糖益生菌粉 | |
TW202002963A (zh) | 用於尿石素(urolithin)化合物之生物合成製備的組合物及方法以及其用途 | |
CN115074298A (zh) | 具有抗幽护胃和消食化积功效的益生菌组合物及其应用 | |
CN110521785A (zh) | 益生菌发酵功能性食品及其制备 | |
CN101406489A (zh) | 微生态复合菌剂及微生态复合菌剂的制备方法 | |
CN111557404A (zh) | 助消化益生菌固体饮料及其制备方法 | |
CN107927793A (zh) | 预防或减轻人体便秘的合生元制剂及其制备方法 | |
CN109432136A (zh) | 一种益生菌组合制剂及其制备方法和应用 | |
CN102742653B (zh) | 一种健脑安神益生菌羊奶片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180420 |
|
RJ01 | Rejection of invention patent application after publication |